61 NORTH BEACON STREET, BOSTON, MA
Amended material disclosure
Material disclosure
Annual Report to Security Holders
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals Enters Underwriting Agreement for 45.86M Shares
Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
Changes in Board, Management or Compensation
Announces Closing of Upsized $85 Million Private Placement
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Submission Upload
Correspondence